Grünenthal acquires Averitas Pharma and establishes commercial footprint in the US

15-Nov-2018 - Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only ...

Mark Fladrich appointed new CCO at Grünenthal

10-May-2017 - The Grünenthal Group announced that Mark Fladrich will take over the position as Chief Commercial Officer (CCO) responsible for the entire Global Commercial Organization. Currently Mark Fladrich is Area Vice President, Southern and Western Europe, at AstraZeneca, based in the UK. He will join ...

Grünenthal Group announced the acquisition of Adhesys Medical

10-Apr-2017 - The acquisition of Adhesys Medical and its highly innovative pipeline of surgical sealants, together with the underlying technology platform, allows Gruenenthal to tap into the global $1 billion surgical sealants market - This contributes to Gruenenthal's ambition to reach EUR2 billion in annual ...

Grünenthal introduces Latin America’s most modern Women’s Health Products plant

16-Jan-2017 - Grünenthal announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m 2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America. The new facility will initially ...

AYOXXA and Grünenthal Completed Research Collaboration

25-Jun-2015 - AYOXXA Biosystems and Grünenthal have completed a first research collaboration to validate detection limits for a biomarker based on AYOXXA’s innovative proprietary technology platform. The focus of this study was to analyze an inflammation marker at very low concentrations released from human ...

Xention and Grünenthal enter Drug Discovery Collaboration in Ion Channel Research

Research collaboration to focus on development of novel pain therapeutics

17-Feb-2011 - XENTION LTD announced that it has entered into a Research Agreement with the Grünenthal Group. Under the terms of the Agreement, Xention and Grϋnenthal will combine their respective expertise in ion channel drug discovery and pain therapy to collaborate in the identification of new drugs to treat ...

Alberto Grua Head of Grünenthal Europe and Australia

23-Sep-2010 - Alberto Gruahas been appointed Grünenthal Europe and Australia Executive Vice President. Beyond the responsibility of the Grünenthal subsidiaries Grünin both continents, Grua will be also a member of the Group Operating Committee of Grünenthal Corporation. Previously, Grua was Responsible for ...

Grünenthal Pharma produces for Biofrontera

14-Apr-2009 - Biofrontera AG and Grünenthal Pharma AG will in the future cooperate on product manufacturing. The companies Biofrontera Pharma GmbH and Grünenthal Pharma AG have signed an agreement for the production of Biofrontera's products BF-200 ALA and Reliéva. BF-200 ALA is a dermatological drug for the ...

Final agreement between Navamedic and Grünenthal for Glucodmed/Flexove marketing in Mexico

02-May-2007 - Navamedic ASA and Grünenthal GmbH have signed the final agreement for marketing and distribution of Glucomed/Flexove in Mexico. On the 22 February 2007, Navamedic ASA announced that it had entered into a Heads of Agreement with Grünenthal for marketing and distribution of Glucomed/Flexove in ...